The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a public consultation on a proposed new Rare Disease Therapies Framework that would introduce significant regulatory innovation to the UK’s rare disease landscape – and the MHRA is calling on the pharmaceutical and life sciences industries to play a central role in shaping the final framework. The draft framework sets out a technology-agnostic regulatory […]